Elastagen snags A$13 mln Series B
Elastagen Pty Ltd, an Australian developer of products based on recombinant human tropoelastin platform technology, has raised A$13 milion in Series B funding. The investors included Korea Investment Partners, AMOREPACIFIC Ventures, Wellcome Trust, Brandon Capital Partners, GBS Ventures and ATP Innovations. In addition to the funding, Sangwoo Lee of KIP has been added to Elastagen's board of directors.
7 January 2016•3 mins read
